CASES Insights Into Breast Cancer Southwest 2020

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. Insights on current treatment practice attitudes toward recently introduced and upcoming agents

Southwest – February 21, 2020
Purchase Report

Faculty Chair

Mark Pegram, MD

Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, Palo Alto, CA, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following breast cancer therapies were obtained

  • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
  • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
  • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.